CR 002

Drug Profile

CR 002

Alternative Names: CR002

Latest Information Update: 10 Sep 2008

Price : $50

At a glance

  • Originator Amgen; CuraGen Corporation
  • Developer CuraGen Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Platelet-derived growth factor D antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy

Highest Development Phases

  • No development reported Diabetic nephropathies; IgA nephropathy; Systemic lupus erythematosus

Most Recent Events

  • 10 Sep 2008 No development reported - Preclinical for Systemic lupus erythematosus in USA (IV)
  • 10 Sep 2008 No development reported - Phase-I for IgA nephropathy in USA (IV)
  • 10 Sep 2008 No development reported - Preclinical for Diabetic nephropathies in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top